An Open-Label, Randomized, Comparative 3-Way Cross-Over Study to Evaluate the Effect of Food on the 24-Hour Intragastric pH at Day 5 After Twice Daily Oral Administration of PN 200 (Omeprazole/Naproxen) in Healthy Volunteers

NCT00442208 | Completed Phase 1 DMC

• 1 other identifier: PN200-105
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

Primary: To compare the pharmacodynamic efficacy of PN 200 in controlling intragastric pH (percent time pH\> 4.0) following twice daily administration at different dosing times relative to food (30 or 60 minutes prior to food or taken togeterh with food) on Day 5.

Conditions

Healthy

Keywords

Healthy adults; Phase I

Outcome Measures

Primary Outcomes (1)

• To compare the pharmacodynamic efficacy of PN 200 in controlling intragastric pH (percent time pH > 4.0)

Secondary Outcomes (1)

• To evaluate the effect of different dosing times of PN 200 on the pharmacokinetic properties of omeprazole

Interventions

PN 200 DRUG

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male or non-lactating, non-pregnant female subjects who are 18-55 years of age
• Female subjects are eligible for participation in the study if they are of:
• Non-childbearing potential (i.e., physiologically incapable of becoming pregnant); or,
• Childbearing potential, have a negative pregnancy test (urine) at screening, and at least one of the following applies or is agreed to by the subject:
• Female sterilization or sterilization of male partner; or,
• Hormonal contraception by oral route, implant, injectable, vaginal ring; or,
• Any intrauterine device (IUD) with published data showing that the lowest expected failure rate is less than 1% per year;
• Double barrier method (2 physical barriers or 1 physical barrier plus spermicide); or
• Any other method with published data showing that the lowest expected failure rate is less than 1% per year
• Physical examination findings within normal limits for age
• Able to understand and comply with study procedures required and able and willing to provide written informed consent prior to any study procedures being performed

You may not qualify if:

• History of hypersensitivity, allergy or intolerance to omeprazole or other proton-pump inhibitors
• History of hypersensitivity, allergy or intolerance to any NSAID (including aspirin) and/or a history of NSAID-induced symptoms of asthma, rhinitis, and/or nasal polyps
• History of peptic ulcer disease or other acid related gastrointestinal symptoms
• Participation in any study of an investigational treatment in the 4 weeks before screening or participation in another study at any time during the period of this study
• Any significant medical illness that would contraindicate participation in the study
• Gastrointestinal disorder or surgery leading to impaired drug absorption
• Any significant mental illness, such as schizophrenia or bipolar disorder
• Cardio- or cerebrovascular disease, based on history or risk factors, or clinically significant ECG in the investigator's opinion
• Personal or family history of an inherited or acquired bleeding disorder
• Positive test result for H pylori at screening

Sponsors & Collaborators

• POZEN: lead

Study Sites (1)

Pozen Inc.

Chapel Hill, North Carolina, 27517, United States

Location

MeSH Terms

Interventions

Isradipine

Intervention Hierarchy (Ancestors)

Dihydropyridines; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• David Taylor

  POZEN

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Expanded Access: Yes

Study Record Dates

• First Submitted: February 28, 2007
• First Posted: March 1, 2007
• Study Start: January 1, 2007
• Primary Completion: February 1, 2008
• Study Completion: February 1, 2008
• Last Updated: April 22, 2008

Record last verified: 2008-04

Locations

US (1)